Melinta Therapeutics, Inc. (NASDAQ:MLNT)
| 7.10 Delayed Data As of Jun 22 |  -0.35 / -4.70%Today’s Change | 5.20 Today|||52-Week Range 24.25 | -55.06% Year-to-Date |
Latest MLNT News | Press Releases
No recent news for Melinta Therapeutics, Inc..
Today’s Trading
| Previous close | 7.45 |
| Today’s open | 7.45 |
| Day’s range | 7.00 - 7.50 |
| Volume | 813,865 |
| Average volume (3 months) | 309,909 |
| Market cap | $244.6M |
Data as of 4:00pm ET, 06/22/2018
Growth & Valuation
| Earnings growth (last year) | -86.84% |
| Earnings growth (this year) | +79.23% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +87.97% |
| P/E ratio | 0.0 |
| Price/Sales | 1.67 |
| Price/Book | 2.37 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ACRXAcelRx Pharmaceutica... | -0.05 | -1.23% |
| CDMOAvid Bioservices Inc | +0.26 | +7.95% |
| RDHLRedhill Biopharma Lt... | +0.06 | +0.77% |
| TRVNTrevena Inc | -0.04 | -2.40% |
Data as of 4:00pm ET, 06/22/2018
Financials
| Next reporting date | August 8, 2018 |
| EPS forecast (this quarter) | -$1.23 |
| Annual revenue (last year) | $33.9M |
| Annual profit (last year) | -$58.9M |
| Net profit margin | -173.98% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Daniel Mark Wechsler |
CFO, Secretary & Principal Accounting Officer Paul Estrem |
Corporate headquarters New Haven, Connecticut |
Forecasts
